Wells Fargo analyst Eva Fortea Verdejo raised the firm’s price target on Revolution Medicines (RVMD) to $70 from $67 and keeps an Overweight rating on the shares. The firm thought Wednesday’s update supports the company’s strategy of moving daraxonrasib to earlier lines in mPDAC. Additionally, the 2L updated data suggests daraxonrasib is well positioned to hit stats in RASolute302, Wells adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Promising Potential of Daraxonrasib in Pancreatic Cancer Boosts Buy Rating for Revolution Medicines
- Promising Clinical Trials and Strategic Design Drive Buy Rating for Revolution Medicines
- Revolution Medicines Reports Promising Phase 1 Study Results
- Leerink says competitor data suggest promising view for Revolution’s zoldonrasib
- Revolution Medicines initiated with a Buy at Truist